Biomarkers of liver diseases.
ALT
Biomarkers
Fibrosis
HMGB1
Liver
NAFLD
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
26
03
2023
accepted:
05
07
2023
medline:
29
8
2023
pubmed:
24
7
2023
entrez:
23
7
2023
Statut:
ppublish
Résumé
The liver is one of the pivotal organs in the human body and is fundamentally responsible for detoxification and metabolism. Various disorders such as non-alcoholic fatty liver disease, fibrosis, cirrhosis, hepatocellular carcinoma, and hepatitis are associated with improper functions of the liver. Hence, biomarkers are needed to determine the severity. Further, many liver enzymes, including the cascade of aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), and total bilirubin (TBIL), are conventional liver biomarkers. They are not, however, unique to the liver; hence, efforts are being made to identify the precise biomarkers for liver illness that can target liver diseases. HMGB1, cytokeratin 18 (K18), glutathione-S-transferase-α (GST-α), glutamate dehydrogenase (GLDH), malate dehydrogenase (MDH), and microRNAs (miRNA) are a few examples of developing biomarkers used to detect many liver diseases. Hence, the review has highlighted various novel biomarkers of the liver so that various pathophysiological pathways and treatments can be made easier.
Identifiants
pubmed: 37482588
doi: 10.1007/s11033-023-08666-0
pii: 10.1007/s11033-023-08666-0
doi:
Substances chimiques
Alanine Transaminase
EC 2.6.1.2
Biomarkers
0
Aspartate Aminotransferases
EC 2.6.1.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7815-7823Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ozougwu JC (2017) Physiology of the liver. Int J Res Pharm Biosci 4(8):13–24
Ozougwa JC, Eyo JE (2014) Hepatoprotective effects of Allium cepa (onion) extracts against paracetamol-induced liver damage in rats. Afr J Biotechnol 13(26): 2679–2688
Moore KL, Dalley AF, Agur AM (2013) Clinically oriented anatomy. Lippincott Williams & Wilkins
Guyton AC, Hall JE (1986) Textbook of medical physiology. Saunders, Philadelphia
Yang X, Schnackenberg LK, Shi Q, Salminen WF (2014) Hepatic toxicity biomarkers. In: Biomarkers in toxicology, pp 241–259. Academic Press
Klaassen C (2007) Casarett and Doull’s toxicology: the basic science of poisons. McGraw Hill Professional, New York
Shakya AK (2020) Drug-induced hepatotoxicity and hepatoprotective medicinal plants: a review. Indian J Pharm Educ Res 54(2):234–250
doi: 10.5530/ijper.54.2.28
Maqbool M, Rasool S, Dar MA, Bashir R, Khan M (2019) Hepatotoxicity and hepatoprotective agents: a mini review. PharmaTutor 7(9):34–40
Czaja MJ (2004) Forms, of hepatotoxin-induced liver injury. Encycl Gastroenterol 2:365
doi: 10.1016/B0-12-386860-2/00367-1
Gulati K, Reshi MR, Rai N, Ray A (2018) Hepatotoxicity: its mechanisms, experimental evaluation and protective strategies. Am J Pharmacol 1(1): 1004
Lynch T, Neff AP (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76(3):391–396
pubmed: 17708140
Sivakrishnan S (2019) Liver disease overview. World J Pharm Pharmaceut Sci 8(1):1385–1395
Paniagua AC, Amariles P (2017) Hepatotoxicity by drugs. In: Pharmacokinetics and adverse effects of drugs-mechanisms and risks factors. InTech
Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62(6):481–492
pubmed: 19474352
doi: 10.1136/jcp.2008.058248
Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59(2):661–670
pubmed: 24037963
doi: 10.1002/hep.26709
Zhang X, Ouyang J, Thung SN (2013) Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis 17(4):547–564
pubmed: 24099017
doi: 10.1016/j.cld.2013.07.004
Hayashi PH, Fontana RJ (2014) Clinical features, diagnosis, and natural history of drug-induced liver injury. In: Seminars in liver disease, vol 34, no 02, pp 134–144. Thieme Medical Publishers
Yang X, Salminen WF, Schnackenberg LK (2012) Current and emerging biomarkers of hepatotoxicity. Curr Biomarker Find 2:43
Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T (2020) Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol 30(10):1667
doi: 10.3389/fphar.2019.01667
Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. CMAJ 172(3):367–379
pubmed: 15684121
pmcid: 545762
doi: 10.1503/cmaj.1040752
Padda MS, Sanchez M, Akhtar AJ, Boyer JL (2011) Drug-induced cholestasis. Hepatology 53(4):1377–1387
pubmed: 21480339
doi: 10.1002/hep.24229
Meunier L, Larrey D (2019) Drug-induced liver injury: biomarkers, requirements, candidates, and validation. Front Pharmacol 11(10):1482
doi: 10.3389/fphar.2019.01482
Anadón A, Castellano V, Martínez-Larrañaga MR (2014) Biomarkers of drug toxicity. In: Biomarkers in toxicology, pp 593–607. Academic Press
Ni YA, Chen H, Nie H, Zheng B, Gong Q (2021) HMGB1: an overview of its roles in the pathogenesis of liver disease. J Leukoc Biol 110(5):987–998
doi: 10.1002/JLB.3MR0121-277R
Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D (2013) Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 19(1):357–366
pubmed: 24306421
pmcid: 3883963
doi: 10.2119/molmed.2013.00099
Khambu B, Yan S, Huda N, Yin XM (2019) Role of high-mobility group box-1 in liver pathogenesis. Int J Mol Sci 20(21):5314
pubmed: 31731454
pmcid: 6862281
doi: 10.3390/ijms20215314
Church RJ, Watkins PB (2017) The transformation in biomarker detection and management of drug-induced liver injury. Liver Int 37(11):1582–1590
pubmed: 28386997
pmcid: 5632128
doi: 10.1111/liv.13441
Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, Hou YJ, Chang YX, Tu QQ, Feng GS, Shen F (2011) Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54(5):1620–1630
pubmed: 21809356
doi: 10.1002/hep.24552
Yates KP, Deppe R, Comerford M, Masuoka H, Cummings OW, Tonascia J, Chalasani N, Vuppalanchi R, NASH CRN (2017) Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. PloS ONE 12(11): e0185813
Wenfeng Z, Wu Y, Di M, Gong J, Chuanxin W, Chun H (2015) Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Ann Hepatol 13(5):489–495
doi: 10.1016/S1665-2681(19)31247-5
Ge X, Arriazu E, Magdaleno F, Antoine DJ, dela Cruz R, Theise N, Nieto N (2018) High mobility group box‐1 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice. Hepatology 68(6): 2380–2404
Wang FP, Li L, Li J, Wang JY, Wang LY, Jiang W (2013) High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS ONE 8(5):e64373
pubmed: 23696886
pmcid: 3655989
doi: 10.1371/journal.pone.0064373
Kao YH, Jawan B, Goto S, Hung CT, Lin YC, Nakano T, Hsu LW, Lai CY, Tai MH, Chen CL (2008) High-mobility group box 1 protein activates hepatic stellate cells in vitro. In: Transplantation proceedings, vol 40, no 8, pp 2704–2705. Elsevier
Zhang Z, Lin C, Peng L, Ouyang Y, Cao Y, Wang J, Friedman SL, Guo J (2012) High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. Life Sci 91(5–6):207–212
pubmed: 22841886
doi: 10.1016/j.lfs.2012.07.009
Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A (2012) High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55(6):1863–1875
pubmed: 22234969
doi: 10.1002/hep.25572
Ye L, Zhang Q, Cheng Y, Chen X, Wang G, Shi M, Zhang T, Cao Y, Pan H, Zhang L, Wang G (2018) Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion. J Immunother Cancer 6(1):1–5
doi: 10.1186/s40425-018-0451-6
Lv G, Wu M, Wang M, Jiang X, Du J, Zhang K, Li D, Ma N, Peng Y, Wang L, Zhou L (2017) miR-320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma. Liver Int 37(9):1354–1364
pubmed: 28317284
doi: 10.1111/liv.13424
Li H, Huang W, Luo R (2015) Retracted article: the microrna-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1. Diagn Pathol 10(1):1–1
doi: 10.1186/s13000-015-0323-z
Zhang Y, Yao YM, Huang LF, Dong N, Yu Y, Sheng ZY (2011) The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 31(2):249–257
pubmed: 21087077
doi: 10.1089/jir.2010.0019
Ding JW, Zheng XX, Zhou T, Tong XH, Luo CY, Wang XA (2016) HMGB1 modulates the Treg/Th17 ratio in atherosclerotic patients. J Atheroscler Thromb 23(6):737–745
pubmed: 26830200
pmcid: 7399277
doi: 10.5551/jat.31088
Shi Y, Sandoghchian Shotorbani S, Su Z et al (2012) Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012:295081
pubmed: 22110531
doi: 10.1155/2012/295081
Sitia G, Iannacone M, Müller S, Bianchi ME, Guidotti LG (2007) Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 81(1):100–107
pubmed: 16935945
doi: 10.1189/jlb.0306173
Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201(7):1135–1143
pubmed: 15795240
pmcid: 2213120
doi: 10.1084/jem.20042614
Nace GW, Huang H, Klune JR, Eid RE, Rosborough BR, Korff S, Li S, Shapiro RA, Stolz DB, Sodhi CP, Hackam DJ (2013) Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology 58(1):374–387
pubmed: 23460269
doi: 10.1002/hep.26346
Cai C, Shi X, Korff S, Zhang J, Loughran PA, Ruan X, Zhang Y, Liu L, Billiar TR (2013) CD14 contributes to warm hepatic ischemia-reperfusion injury in mice. Shock (Augusta, Ga.) 40(2): 115
Huebener P, Pradere JP, Hernandez C et al (2015) The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest 125:539–550
doi: 10.1172/JCI76887
Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138(6):1379–1394 ([PubMed: 9298992])
pubmed: 9298992
pmcid: 2132555
doi: 10.1083/jcb.138.6.1379
Mannery YO, McClain CJ, Vos MB (2011) Keratin 18, apoptosis, and liver disease in children. Curr Pediatr Rev 7(4): 310–315
Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FC, Björklund B, Nap M, Jörnvall H (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187(5):567–572
pubmed: 10398123
doi: 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J
de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA (2008) Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10(10):1041–1048
pubmed: 18813353
pmcid: 2546590
doi: 10.1593/neo.08620
Tarrant J (2017) Emerging translatable safety biomarkers. Comprehensive medicinal chemistry III, pp 255–284. Elsevier, Oxford
Mastorodemos V, Kotzamani D, Zaganas I, Arianoglou G, Latsoudis H, Plaitakis A (2009) Human GLUD1 and GLUD2 glutamate dehydrogenase localize to mitochondria and endoplasmic reticulum. Biochem Cell Biol 87(3):505–516
pubmed: 19448744
doi: 10.1139/O09-008
O'brien PJ, Slaughter MR, Polley SR, Kramer K (2002) Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 36(3): 313–321
McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H (2012) The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Investig 122(4):1574–1583
pubmed: 22378043
pmcid: 3314460
doi: 10.1172/JCI59755
Giffen PS, Pick CR, Price MA, Williams A, York MJ (2002) Alpha-glutathione S-transferase in the assessment of hepatotoxicity—its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol Pathol 30(3):365–372
pubmed: 12051554
doi: 10.1080/01926230252929945
Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245(3):194–205
pubmed: 18291570
doi: 10.1016/j.tox.2007.11.021
Smith GS, Walter GL, Walker RM (2013) Clinical pathology in non-clinical toxicology testing. In: Haschek and Rousseaux’s handbook of toxicologic pathology, pp 565–594. Academic Press
Zelewski M, Swierczyński J (1991) Malic enzyme in human liver. Intracellular distribution, purification and properties of cytosolic isozyme. Eur J Biochem 201(2): 339–345
Zieve L, Anderson WR, Dozeman R, Draves K, Lyftogt C (1985) Acetaminophen liver injury: sequential changes in two biochemical indices of regeneration and their relationship to histologic alterations. J Lab Clin Med 105(5):619–624
pubmed: 3989355
Kawai M, Hosaki S (1990) Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease. Clin Biochem 23(4):327–334
pubmed: 2171815
doi: 10.1016/0009-9120(90)80064-P
Misra MK, Khanna AK, Sharma R, Srinivasan S (1991) Serum malate dehydrogenase (MDH) in portal hypertension—its value as a diagnostic and prognostic indicator. Indian J Med Sci 45(2):31–34
pubmed: 2060978
Marrer E, Dieterle F (2010) Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 243(2):167–179
pubmed: 20036272
doi: 10.1016/j.taap.2009.12.015
Koo DJ, Zhou M, Chaudry IH, Wang P (2000) Plasma α-glutathione S-transferase: a sensitive indicator of hepatocellular damage during polymicrobial sepsis. Arch Surg 135(2):198–203
pubmed: 10668881
doi: 10.1001/archsurg.135.2.198
Loguercio C, Tuccillo C, Caporaso N, Blanco GD, Morisco F, Guerriero C, Di Santolo SS, Valenza LM, Blanco CD (1998) Determination of plasma alpha‐glutathione S‐transferases in patients with HCV‐related chronic infection: its significance and possible clinical relevance. Liver 18(3): 166–172
Suehiro T, Matsumata T, Shikada Y, Shimada M, Shirabe K, Sugimachi K (2004) Change in alpha glutathione s-transferase levels during liver resection. Hepatogastroenterology 51(60):1747–1750
pubmed: 15532818
Czuczejko J, Mila-Kierzenkowska C, Szewczyk-Golec K (2019) Plasma α-glutathione S-transferase evaluation in patients with acute and chronic liver injury. Can J Gastroenterol Hepatol 20:2019
Higuchi H, Adachi Y, Wada H, Kanno M, Satoh T (2001) Comparison of plasma α glutathione S-transferase concentrations during and after low-flow sevoflurane or isoflurane anaesthesia. Acta Anaesthesiol Scand 45(10):1226–1229
pubmed: 11736674
doi: 10.1034/j.1399-6576.2001.451009.x
Rodrigo L, Hernández AF, Lopez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chemico-Biol Interact 137(2): 123–137
Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J (2002) Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 48(2):261–268
pubmed: 11805006
doi: 10.1093/clinchem/48.2.261
Feingold KR, Memon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139(2):307–315
pubmed: 9712337
doi: 10.1016/S0021-9150(98)00084-7
Meneses-Lorente G, Guest PC, Lawrence J, Muniappa N, Knowles MR, Skynner HA, Salim K, Cristea I, Mortishire-Smith R, Gaskell SJ, Watt A (2004) A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol 17(5):605–612
pubmed: 15144217
doi: 10.1021/tx034203n
Furlong CE, Cole TB, Jarvik GP, Costa LG (2002) Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3(3):341–348
pubmed: 12052142
doi: 10.1517/14622416.3.3.341
Ha MJ, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15: 509–524
Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39(16):7223–7233
pubmed: 21609964
pmcid: 3167594
doi: 10.1093/nar/gkr254
Arrese M, Eguchi A, Feldstein AE (2015) Circulating microRNAs: emerging biomarkers of liver disease. In: Seminars in liver disease, vol 35, no 01, pp 043–054. Thieme Medical Publishers
Pirola CJ, Gianotti TF, Castaño GO, Mallardi P, San Martino J, Ledesma MM, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S (2015) Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64(5):800–812
pubmed: 24973316
doi: 10.1136/gutjnl-2014-306996
Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ (2014) Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol 34(6):726–732
pubmed: 24217942
doi: 10.1002/jat.2960
Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, Hamajima N (2013) Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 23(424):99–103
doi: 10.1016/j.cca.2013.05.021
Longchamps RJ, Abey SK, Martino AC, Henderson WA (2014) Gender-associated cell-free microRNA profiles in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 39(9):997
pubmed: 24689349
pmcid: 4007279
doi: 10.1111/apt.12649
Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10(9):542–552
pubmed: 23689081
pmcid: 4091636
doi: 10.1038/nrgastro.2013.87
Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, Shimotohno K (2011) The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE 6(1):e16081
pubmed: 21283674
pmcid: 3025920
doi: 10.1371/journal.pone.0016081
Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53(1):209–218
pubmed: 20890893
doi: 10.1002/hep.23922
Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. In: Seminars in oncology, vol 38, no 6, pp 752–763. WB Saunders
Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G (2012) Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56(5):1946–1957
pubmed: 22684891
doi: 10.1002/hep.25873
Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci 106(11):4402–4407
pubmed: 19246379
pmcid: 2657429
doi: 10.1073/pnas.0813371106
Su YW, Chen X, Jiang ZZ, Wang T, Wang C, Zhang Y, Wen J, Xue M, Zhu D, Zhang Y, Su YJ (2012) A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS ONE 7(5):e37395
pubmed: 22624025
pmcid: 3356255
doi: 10.1371/journal.pone.0037395
Starkey Lewis PJ et al (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54: 1767–1776
Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G (2012) Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 10(1):1
doi: 10.1186/1479-5876-10-151
Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S (2012) Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56(5):1631–1640
pubmed: 22610915
doi: 10.1002/hep.25849
Ji F, Yang B, Peng X, Ding H, You H, Tien P (2011) Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepatitis 18(7):e242–e251
doi: 10.1111/j.1365-2893.2011.01443.x
Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56(12):1830–1838
pubmed: 20930130
doi: 10.1373/clinchem.2010.147850
Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16(4):885–893
pubmed: 88265
doi: 10.1016/0092-8674(79)90103-X
Nagoshi S (2014) Osteopontin: versatile modulator of liver diseases. Hepatol Res 44(1):22–30
pubmed: 23701387
doi: 10.1111/hepr.12166
Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI, Nieto N (2012) Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin αVβ3 engagement and PI3K/pAkt/NFκB signaling. Hepatology 55(2):594–608
pubmed: 21953216
doi: 10.1002/hep.24701
Kawashima R, Mochida S, Matsui A, YouLuTuZ Y, Ishikawa K, Toshima K, Yamanobe F, Inao M, Ikeda H, Ohno A, Nagoshi S (1999) Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 256(3):527–531
pubmed: 10080931
doi: 10.1006/bbrc.1999.0372
Bruha R, Vitek L, Smid V (2020) Osteopontin—a potential biomarker of advanced liver disease. Ann Hepatol 19(4):344–352
pubmed: 32005637
doi: 10.1016/j.aohep.2020.01.001
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328(25):1797–1801
pubmed: 7684822
doi: 10.1056/NEJM199306243282501
Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. J Hepatol 43(3):434–441
pubmed: 16136646
doi: 10.1016/j.jhep.2005.03.019
Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y (2002) Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 49(43):235–238
pubmed: 11941963
Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M (2001) Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α-fetoprotein alone and those seropositive for des-γ-carboxy prothrombin alone 1. J Gastroenterol Hepatol 16(11):1290–1296
pubmed: 11903749
doi: 10.1046/j.1440-1746.2001.02610.x
Waikar Y (2019) Biomarkers of liver injury. Indian J Pediatr 8(2):70
Lala V, Zubair M, Minter D (2023) Liver function tests. StatPearls
Adigun OO, Yarrarapu SN, Zubair M, Khetarpal S (2023) Alpha fetoprotein. StatPearls
Nourkami-Tutdibi N, Graf N, Beier R, Zemlin M, Tutdibi E (2020) Plasma levels of osteopontin from birth to adulthood. Pediatr Blood Cancer 67(7):e28272
pubmed: 32227460
doi: 10.1002/pbc.28272
Štros M, Polanská EV, Hlaváčová T, Skládal P (2022) Progress in assays of HMGB1 levels in human plasma—the potential prognostic value in COVID-19. Biomolecules 12(4):544
pubmed: 35454134
pmcid: 9031208
doi: 10.3390/biom12040544